Real-World Effectiveness of Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma: the Aron-2 Study

AuthID
P-00Y-H1C
43
Author(s)
Santoni, M
·
Myint, ZW
·
Buettner, T
·
Takeshita, H
·
Okada, Y
·
Lam, ET
·
Gilbert, D
·
[+4]·
[+4]·
[+8]·
[+4]·
[+2]·
[+1]·
Rizzo, A
·
Monteiro, FSM
·
Battelli, N
·
Calabro, F
·
Porta, C
Document Type
Article in Press
Year published
2023
Published
in CANCER IMMUNOLOGY IMMUNOTHERAPY, ISSN: 0340-7004
Indexing
Publication Identifiers
Pubmed: 37248424
Scopus: 2-s2.0-85160408484
Wos: WOS:000999295300003
Source Identifiers
ISSN: 0340-7004
Export Publication Metadata
Marked List
Info
At this moment we don't have any links to full text documens.
Name Order Name   Name Order Name   Name Order Name
1 Santoni, M;   2 Myint, ZW;   3 Buettner, T;
4 Takeshita, H;   5 Okada, Y;   6 Lam, ET;
7 Gilbert, D;   8 Kuronya, Z;   9 Tural, D;
10 Pichler, R;   11 Grande, E;   12 Crabb, SJ;
13 Kemp, R;   14 Massari, F;   15 Scagliarini, S;
16 Iacovelli, R;   17 Vau, N;   18 Basso, U;
19 Maruzzo, M;   20 Molina Cerrillo, J;   21 Galli, L;
22 Bamias, A;   23 De Giorgi, U;   24 Zucali, PA;
25 Rizzo, M;   26 Seront, E;   27 Popovic, L;
28 Caffo, O;   29 Buti, S;   30 Kanesvaran, R;
31 Kopecky, J;   32 Kucharz, J;   33 Zeppellini, A;
34 Fiala, O;   35 Landmesser, J;   36 Ansari, J;
37 Giannatempo, P;   38 Rizzo, A;   39 Zabalza, IO;
40 Monteiro, FSM;   41 Battelli, N;   42 Calabro, F;
43 Porta, C;